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Naynesh R. Kamani,1 Mark C. Walters,2 Shelly Carter,3 Victor Aquino,4
Joel A. Brochstein,5 Sonali Chaudhury,6 Mary Eapen,7 Brian M. Freed,8 Michael Grimley,9
John E. Levine,10 Brent Logan,7 Theodore Moore,11 Julie Panepinto,7 Suhag Parikh,12
Michael A. Pulsipher,13 Jane Sande,1 Kirk R. Schultz,14 Stephen Spellman,15 Shalini Shenoy16The Sickle Cell Unrelated Donor Transplant Trial (SCURT trial) of the Blood and Marrow Transplant Clinical
Trials Network (BMT CTN) is a phase II study of the toxicity and efficacy of unrelated donor hematopoietic
cell transplantation in children with severe sickle cell disease (SCD) using a reduced-intensity conditioning
regimen. Here we report the results for the cord blood cohort of this trial. Eight children with severe SCD
underwent unrelated donor cord blood transplantation (CBT) following alemtuzumab, fludarabine, and
melphalan. Cyclosporine or tacrolimus and mycophenolate mofetil were administered for graft-versus-host
disease (GVHD) prophylaxis. Donor/recipient HLA match status was 6 of 6 (n 5 1) or 5 of 6 (n 5 7), based
on low/intermediate-resolution molecular typing at HLA -A, -B, and high-resolution typing at -DRB1. Median
recipient age was 13.7 years (range: 7.4-16.2 years), and median weight was 35.0 kg (range: 25.2-90.2 kg).
The median precryopreservation total nucleated cell dose was 6.4  107 /kg (range: 3.1-7.6), and the median
postthaw infused CD34 cell dose was 1.5 105 /kg (range: 0.2-2.3). All patients achieved neutrophil recovery
(absolute neutrophil count.500/mm3) by day 33 (median: 22 days). Three patients who engrafted had 100%
donor cells by day 100, which was sustained, and 5 patients had autologous hematopoietic recovery. Six of 8
patients had a platelet recovery to .50,000/mm3 by day 100. Two patients developed grade II acute GVHD.
Of these, 1 developed extensive chronic GVHD and died of respiratory failure 14 months posttransplantation.
With amedian follow-up of 1.8 years (range: 1-2.6), 7 patients are alive with a 1-year survival of 100%, and 3 of 8
are alive without graft failure or disease recurrence. Based upon the high incidence of graft rejection after
unrelated donor CBT, enrollment onto the cord blood arm of the SCURT trial was suspended. However,
because this reduced-intensity regimen has demonstrated a favorable safety profile, this trial remains open to
enrollment for unrelated marrow donor transplants. Novel approaches aimed at improving engraftment will
be needed before unrelated CBT can be widely adopted for transplanting patients with severe SCD.
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of 85% in children following a myeloablative prepara-
tive regimen of busulfan, cyclophosphamide, and
antithymocyte globulin [1]. In addition, long-term
follow-up studies from this and other patient series
have demonstrated cessation of SCD-related events
after successful HCT, even among those with
mixed donor-host hematopoietic chimerism [2-5].
However, these observations have done little to
expand the application of HCT for SCD because
fewer than 20% of individuals have HLA-identical
sibling donors and because there are ongoing concerns
about the toxicity of this therapy. To address these
challenges, a prospective multicenter, phase II clinical
trial of HCT was initiated using a reduced-intensity
conditioning regimen and well-matched unrelated
donor cells. The overarching goal of this ongoing trial
is to assess the toxicity and efficacy of such an approach
and to expand the availability of HCT so that more
individuals with severe SCD might benefit from this
treatment option.
The hypothesis for this reduced-intensity regimen
is the premise that host immune ablation can support
successful donor cell engraftment without myeloabla-
tion. The trial was developed based on the results of
a preliminary study of reduced-intensity HCT in 16
children with nonmalignant disorders who received
alemtuzumab, fludarabine, and melphalan before
HLA-identical sibling or unrelated donor HCT
[6,7]. Graft rejection and graft-versus-host disease
(GVHD) rates were low, and prompt engraftment
occurred after transplantation from both related and
unrelated donors. No late graft rejection was noted
despite the early cessation of postgrafting immunosup-
pression. The regimen-related toxicity observed was
early and related primarily to infections associated with
this highly immunosuppressive conditioning regimen.
This experience was distinctly different from the very
high rate of graft rejection that was observed in several
small series after nonmyeloablative HCT for SCD
[8,9], and in another recent trial of nonmyeloablative
matched sibling donor transplantation for adults with
SCD where postgrafting immunosuppression had to
be extended indefinitely to prevent late graft rejection
[10]. Thus, we reasoned that our reduced-intensity
conditioning approach might be sufficiently immu-
noablative to suppress host-versus-graft rejection and
promote engraftment of donor cells after unrelated
donor HCT in SCD. With careful attention to infec-
tion prevention and preemptive treatment of viral
reactivation, it was also our aim to reduce the short-
and long-term toxicity of transplantation.
The preliminary results of the ongoing phase II
trial strongly suggest that this is a safe approach to
unrelated donor HCT for SCD. However, we have
observed a high rate of graft rejection after unrelated
donor cord blood transplantation (CBT), which hasresulted in closure of the cord blood arm of the study
and caused us to look more carefully at factors that
may have contributed to graft rejection. Here, we pres-
ent the preliminary results for the cord blood cohort of
this multicenter trial, which continues to enroll
patients with 8 of 8 HLA-allele matched unrelated
bone marrow donors.STUDY DESIGN AND METHODS
Study Design
The Sickle Cell Unrelated Donor Transplant
Trial (SCURT) is a phase II multicenter trial designed
to estimate the efficacy and toxicity of unrelated donor
HCT using a reduced-intensity conditioning regimen
in children with SCD and high-risk features. It was
initiated in 2008 and included 2 cohorts based on the
donor hematopoietic stem cell source. The primary
objective of the study was to determine EFS at 1 year
after unrelated donor transplantation using either
bone marrow or cord blood as a stem cell source.
The secondary objectives included the determination
of the effects of HCT on clinical and laboratory man-
ifestations of SCD and the incidence of HCT compli-
cations such as transplant-related toxicity, graft failure,
and acute and chronic GVHD (aGVHD, cGVHD).
Stopping rules for the study included unacceptable
rates of mortality, GVHD, or graft rejection.Patients
The protocol was approved by the institutional
review board at each of the 7 institutions that enrolled
patients and by the institutional review board of
the National Marrow Donor Program. Consent was
obtained from legal guardians for all patients before
enrollment; assents were obtained where appropriate.
In addition, before enrollment, an independent exter-
nal review committee approved enrollment by ensur-
ing that the patient met disease-related eligibility
criteria. An important eligibility criteria design consid-
eration was to enroll only patients with SCD manifes-
tations associated with poor long-term outcomes
despite optimal supportive care. For the patients
described in this report, eligibility included recipients
3-16 years of age with severe SCD with 1 or more of
the following: (1) a clinically significant neurologic
event (overt stroke) defined as any neurologic defect
lasting .24 hours and accompanied by an infarct on
cerebral magnetic resonance imaging; or, (2) a mini-
mum of 2 episodes of acute chest syndrome (ACS)
within the preceding 2-year period defined as new
pulmonary alveolar consolidation involving at least
1 complete lung segment (associated with acute
symptoms including fever, chest pain, tachypnea,
wheezing, rales, or cough that is not attributed to
Biol Blood Marrow Transplant 18:1265-1272, 2012 1267Unrelated Donor CBT for Children with SCDasthma or bronchiolitis) despite adequate supportive
care measures; or, (3) a history of 3 or more severe
pain events or vaso-occlusive crises (VOC) per year
in the 2 years before enrollment. An additional crite-
rion for patients with recurrent ACS or VOC was
the requirement that they either fail to significantly
benefit from or were unable or unwilling to continue
supportive care therapy that included hydroxyurea.
Patients with HLA-matched sibling donors, HIV
seropositivity, Lansky performance score \50, or
uncontrolled bacterial, viral, or fungal infections
were ineligible. Multiorgan assessment performed
before enrollment was required to demonstrate the
following: serum creatinine\1.5 upper limit of nor-
mal for age and glomerular filtration rate .100 mL/
min/1.73 m2; alanine aminotransferase and aspartate
aminotransferance \5 times upper limits of normal
and direct serum bilirubin\2 upper limit of normal;
left ventricular ejection fraction.40% or left ventric-
ular shortening fraction .26%; and carbon monoxide
diffusing capacity .40% of predicted (corrected for
hemoglobin). For patients who had received regular
blood transfusions for over a year and whose serum
ferritin was .1000 ng/mL, a liver biopsy had to dem-
onstrate the absence of cirrhosis or bridging fibrosis.
The Hb S percentage had to be #45% 7 days before
initiation of alemtuzumab. Iron chelation and/or
hydroxyurea had to be discontinued 48 hours before
alemtuzumab.
Donor Selection
The donor/recipient HLA match for umbilical
cord blood transplantation (UCBT) was accomplished
by low/intermediate-resolution molecular typing for
class I HLA-A and -B alleles, and high-resolution
molecular typing for HLA-DRB1 alleles (original
HLA match). For the purpose of this report, high-
resolution molecular typing for HLA-A, -B, -C, and
-DRB1 alleles was retrospectively reviewed and
reported as the final HLA match. The selected cord
blood unit (CBU) was required to be$5 of 6 matched
and provide a minimum of 3 107 total nucleated cells
(precryopreservation) per kilogram (kg) of recipient
weight.
Preparative Regimen
All patients received increasing doses of alem-
tuzumab intravenously daily for 3 days (10 mg, 15
mg, and 20 mg) starting on day221 after a 3-mg intra-
venous (i.v.) test dose. Patients were discharged after
alemtuzumab administration and readmitted to start
fludarabine 30 mg/m2 daily from day 28 to day 24.
Melphalan (140 mg/m2/day) was given on day 23 [6].
GVHD prophylaxis consisted of cyclosporine or
tacrolimus andmycophenolate mofetil (MMF). Cyclo-
sporine or tacrolimus was started on day 23 withregular monitoring to maintain therapeutic levels and
continued to day 100, then tapered weekly and discon-
tinued on day 1180 if recipients had no evidence of
GVHD. MMF (1 g i.v. every 8 hours for children
$50 kg or 15 mg/kg i.v. every 8 hours for children
\50 kg) was started on day 23 and given through day
145 or 7 days after engraftment, whichever was later.
Monitoring of MMF levels was not mandated by the
protocol. Granulocyte colony stimulating factor,
5 mg/kg/day, was started on day17 and continued until
neutrophil engraftment.Endpoint Definitions
The primary endpoint of the study was EFS at
1 year posttransplantation.
Primary or late graft rejection, disease recurrence,
or death was considered an event for this endpoint. Pri-
mary graft rejection was defined as the presence of
\20% donor cells as assessed by bone marrow or
peripheral blood chimerism assays on day 42 or the
infusion of a second stem cell product on or before
day 42. Late graft rejection was defined as the presence
of\20% donor-derived hematopoietic cells in periph-
eral blood or bonemarrow after day 42 in a patient with
prior evidence of .20% donor cells or the infusion of
a second stem cell product beyond day 42. Survival
was defined as the time from transplantation to day of
death or day of last follow-up. Neutrophil recovery
was defined as the first day of achieving an absolute
neutrophil count of at least 500/mm3 for 3 consecutive
days. Platelet recovery was defined as the first day
of a minimum of 3 consecutive measurements on
different days that the patient had achieved a platelet
count .50,000/mm3, and was platelet transfusion
independent for aminimumof 7 days. The time to neu-
trophil or platelet recoverywas defined as the time from
transplantation to the first day of engraftment.
Acute GVHD assessments were made every 7 days
to day 100 post-CBT, 6 months, 1 year, and 2 years
after CBT. The grading of aGVHD followed the
GVHD consensus grading scheme and methods of
Weisdorf et al. [11]. Clinically significant infections
were reported posttransplantation by site of infection,
organism, and severity. Readmissions after the initial
discharge following transplantation were reported by
date and primary and secondary reasons for admission.
The Common Terminology Criteria for Adverse
Events version 3.0 was used to report expected grade
3-5 adverse events through 1-year posttransplantation.
Maximum Common Terminology Criteria for Ad-
verse Events grades across all organ systems were
reported monthly for 3 months and at 6 and 12months
posttransplantation.
A truncated sequential probability ratio test for
a binomial outcome was used to monitor for each of
the 3 key safety endpoints, namely overall mortality,
Table 1. Patient Demographics
Patient ID Gender Race
Age at Transplantation
(Years) Disease Type Lansky Score
Indication for
Transplantation
02376 F Black/AA 11.2 Hgb SS 80 VOC
02395 F Black/AA 16.3 Hgb SS 80 Stroke
02497 M Black/AA 14.3 Hgb SS 80 ACS
02541 F Black/AA 7.4 Hgb SS 100 ACS
02611 M Black/AA 13.9 Hgb Sßo thal 100 VOC
02613 F Black/AA 10.9 Hgb SS 100 ACS
02760 F White Hispanic 15.0 Hgb Sß+ thal 100 VOC
02901 F Black/AA 13.6 Hgb SS 100 Stroke
1268 Biol Blood Marrow Transplant 18:1265-1272, 2012N. R. Kamani et al.graft rejection, and GVHD. The stopping rules were
triggered if there was significant evidence that the
day 100 overall mortality rate was .15% based on
the truncated sequential probability ratio test, or
if the day 100 graft rejection rate exceeded 20%, or if
the day 100 grade III-IV GVHD rate exceeded 15%.
Anti-HLA Donor-Specific Antibodies (DSA)
A retrospective analysis for the presence of anti-
HLA DSA was performed in 6 recipients using stored
pretransplantation sera. Donor mismatched HLA al-
leles were identified and recipient DSA response was
screened with the LABScreen Single Antigen HLA
Class I/II Antibody Detection system that uses mi-
crobeads coated with purified Class I or Class II
HLA antigens for the detection of Class I or Class II
HLA antibodies in the patient’s plasma. Each bead in
a LABScreen Single Antigen assay is specific for a sin-
gle HLA antigen, permitting assessment of specificity
for mismatched antigens carried by the donor.
Statistical Analysis
Survival estimates were calculated using the
Kaplan-Meier method. Neutrophil and platelet recov-
eries, aGVHD and cGVHD, and graft rejection/
disease relapse were analyzed using the cause-specific
failure probability method (or cumulative incidence)
[12]. Because of the small sample size, only univariate
analyses were performed.RESULTS
Study Population
Eight patients were enrolled for UCBT at 7 trans-
plant centers. Baseline characteristics are shown in
Table 1. The median age was 13.8 years (range:
7.4-16.2). The primary diagnosis was Hemoglobin
SS disease (n 5 6), Hgb S/b0 Thalassemia (n 5 1),
and Hgb S/b1 Thalassemia (n 5 1). The indication
for CBT was stroke in 2 patients, recurrent ACS in 3
patients, and recurrent VOC in 3 patients. Themedian
precryopreserved total nucleated cell (TNC) dose was
6.4 107/kg (range: 3.1-7.6), and the postthaw infusedTNC and CD341 cell dose/kg were 4.5  107 (range:
2.1-6.3) and 1.5  105 (range: 0.2-2.3), respectively.
Results of donor–recipient blood groups and HLA
matching are shown in Table 2. Based on original
donor–recipient HLA typing, all 8 patients were
matched at 5 of 6HLA antigens. However, at the allele
level high resolution molecular HLA typing for
HLA-A, -B, -C, and -DRB1, all donor/recipient pairs
were mismatched for 1 (n 5 2), 2 (n 5 4), or 3 (n 5 2)
alleles. Of note, both patients who were allele-matched
at the C locus engrafted, whereas 5 of 6 mismatched at
1 or both C loci rejected their grafts. The retrospective
analysis for the presence of anti-HLA donor-specific
antibodies failed to detect DSA in any of the 6
pretransplantation serum samples tested.
Engraftment and Survival
All 8 patients achieved neutrophil recovery with an
absolute neutrophil count .500/mm3 at a median of
22 days (range: 13-33) after CBT. Six of 8 patients
had platelet recovery to 50,000/mm3 by day 100. In 5
patients, blood count recovery was the result of graft
rejection and autologous hematopoietic reconstitu-
tion, as demonstrated by 100% recipient DNA in chi-
merism studies performed on day 42 samples. No late
graft rejections were observed, and the remaining 3 pa-
tients had sustained donor engraftment through last
follow-up. Because of primary graft rejection, the 1-
year EFS was 37.5% (95% confidence interval:
8.7%-67.4%). All graft rejections were nonlethal and
were not characterized by marrow aplasia. With a me-
dian follow-up of 1.8 years (1-2.6), 1-year survival was
100%. The solitary death on this study occurred on
day 430 from complications of cGVHD (Table 3).
Acute GVHD and cGVHD
The maximum GVHD grade was grade II (n5 2).
An additional patient developed a limited skin rash
(grade I). There was 1 case of chronic extensive
GVHD.
Regimen-Related Toxicity
Serious, but reversible, transplant-related neuro-
logic toxicities in the first 100 days developed in
Table 2. Donor–Recipient Characteristics
Patient ID
Original
HLA Match
Donor–Recipient
Allele Level HLA Match
Prior Chronic
Transfusion Therapy
Recipient
Blood Group
Donor
Blood Group
Red-Cell
Alloantibody
Antidonor-Specific
HLA Antibodies
02376 5/6 7/8 Yes B +ve A +ve Yes No
02395 5/6 6/8 Yes A +ve A +ve No No
02497 5/6 5/8 Yes A +ve O -ve Yes Not tested
02541 5/6 6/8 No O +ve O +ve Yes No
02611 5/6 6/8 No O +ve B +ve No No
02613 5/6 6/8 No A +ve B +ve No No
02760 5/6 7/8 No AB +ve O +ve No No
02901 5/6 5/8 Yes B +ve O +ve No Not tested
Biol Blood Marrow Transplant 18:1265-1272, 2012 1269Unrelated Donor CBT for Children with SCD2 patients. One patient, with hypertension, experi-
enced a grade 4 intraventricular hemorrhage with sei-
zures on day 7. A second patient developed posterior
reversible leukoencephalopathy syndrome because of
cyclosporine. Both patients experienced complete
recovery. Two patients had grade 4 liver toxicity,
which was transient. No patient developed idiopathic
pneumonia syndrome or hepatic VOC disease. One
patient developed Epstein-Barr virus reactivation
with posttransplantation lymphoproliferative disease
and a brain abscess in the context of cGVHD, and
eventually died on day 430 from respiratory failure sec-
ondary to pneumonia.
There were a total of 19 infections (bacterial and
viral) reported in 6 of 8 patients, with no infections
reported in 2 patients. These included 9 episodes
of bacteremia (8 Gram-positive organisms, 1 Klebsiella),
3 patientswith cytomegalovirus viremia, 1withEpstein-
Barr virus reactivationprogressing toposttranplantation
lymphoproliferative disorder, 3 with upper respiratory
tract infections (1 adenovirus, 1 parainfluenza-3, and
1 Pseudomonas), 1 with lower respiratory tract
parainfluenza-3 infection, 1 adenovirus gastroenteritis,
and 1 C. difficile enterocolitis.DISCUSSION
Although allogeneic HCT has curative potential
for patients with severe SCD, there are 2major barriers
tomaking this therapy available to eligible patients: the
absence of HLA identical sibling donors and concerns
about the risk of mortality or treatment-related toxic-
ities [13]. In order to circumvent these barriers, we
initiated a clinical trial of a reduced-intensity pre-
parative regimen before unrelated donor HCT for
severe SCD, in particular, relying upon the use of
cord blood as a source of hematopoietic cells for all-
ogeneic transplantation in patients with hemogl-
obinopathies [14,15]. With cord blood as a source of
hematopoietic cells, it was our expectation that the
risk of GVHD would be lower compared with
marrow-derived hematopoietic cells and that $5 of
6 matched CB units would be available for the vast
majority of potential recipients [16,17]. In the firstreport of sibling donor CBT using a myeloablative
regimen in 44 children with hemoglobinopathies, the
EFS was 79% for thalassemia and 90% for SCD with
no treatment-related mortality; all the treatment
failures were related to graft rejection [18]. Thus, we
reasoned that the risk of graft rejection/disease recur-
rence might pose a similar challenge after unrelated
CBT and we applied stringent HLA matching and
cell dose requirements in anticipation of this problem.
Despite these considerations, we observed a high
incidence of graft rejection after CBT (5 of 8 recipi-
ents) that was accompanied by autologous recovery
of sickle erythropoiesis by 6 weeks after transpl-
antation. This experience is consistent with other
reports of graft rejection following nonmyeloablative
or reduced-intensity preparation before CBT, and
suggests that further intensification in the preparative
regimen may be necessary to ensure donor engraft-
ment. An early report of unrelated CBT in 3 children
with SCD included a single case of graft rejection
followed by recovery of autologous hematopoiesis
[19], and successful donor cell engraftment followed
by GVHD in 2 of 3 children. In a subsequent retro-
spective review of a 4-center experience with unrelated
cord blood transplantation in children with SCD that
included 4 additional recipients (n 5 7), 5 patients
received a single CBU matched at 4 of 6 HLA-
antigens and 2 were matched 5 of 6 HLA-antigens.
All 3 patients who received a reduced-intensity regi-
men experienced graft rejection. Of the 4 who received
myeloablative regimens, 3 engrafted and 2 developed
grade III-IV aGVHD [20]. A recent retrospective sur-
vey of UCBT in 51 patients with hemoglobinopathies
conducted by the Center for International Blood and
Marrow Transplant Research with Eurocord and NY
Blood Center participation observed primary graft
failure in 7 of 16 recipients despite the use of myeloa-
blative conditioning therapy in 4 of the 7 patients. A
better disease-free survival among recipients who
received CBT with a TNC content $5  107/kg was
observed [21]. The notion that a larger cellular content
might promote durable engraftment after CBT for
hemoglobinopathies was also suggested in a report
by Jaing et al. [22] of successful durable donor engraft-
ment in 4 of 5 children with thalassemia major who
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of 6HLA-antigens. Thus, CBT from unrelated donors
appears to present unique challenges to a successful
outcome among recipients with hemoglobinopathies.
Another factor that might contribute to the high
incidence of graft rejection that we and others have
observed after CBT for SCD is donor–recipient
HLA incompatibility. In a cohort of 269 patients
with hematologic malignancies undergoing myeloa-
blative bone marrow transplantation frommismatched
related donors, there was a linear correlation between
a higher rate of graft rejection and increasing donor
HLA incompatibility with prior alloimmunization (as
assessed by a positive crossmatch for antidonor lym-
phocytotoxic antibody) [23]. A nonengraftment/graft
failure rate that approached 20% was observed in the
largest trial of unrelated CBT (COBLT) in children
with hematologic malignancies following a myeloabla-
tive regimen [24]. This was primarily attributed to cell
dose and donor–recipient mismatching as a lower cell
dose and a greater degree of HLA mismatching were
associated with higher nonengraftment rates [25-28].
In patients with hemoglobinopathies, these risk
factors are probably amplified by the effect of
multiple transfusion exposures that might sensitize
the recipient to donor alloantigens. In addition, the
cytokine milieu of SCD, which is one of
inflammation and immune activation at the baseline,
might also promote a host-versus-graft reaction and
thereby interfere with engraftment even after myeloa-
blative preparation [29]. Although it is possible this
risk might be overcome by employing more immuno-
suppressive preparative regimens by the addition of ei-
ther antithymocyte globulin or low-dose total body
irradiation as reported in multiply transfused patients
with aplastic anemia [30-32], we found that even the
use of a highly immunosuppressive conditioning
regimen was not sufficient to overcome these factors
in patients with severe SCD.
Although donor–recipient ABO incompatibility
can cause complications such as delayed red blood
cell (RBC) engraftment, pure red cell aplasia, or hemo-
lytic anemia, it is not associated with graft rejection in
patientswith hematologicmalignancies [33].However,
RBC alloimmunization recently was reported as an in-
dependent predictor of HLA alloimmunization [34].
The RBC alloimmunization frequency approaches
25% of SCD patients in the absence of extended phe-
notype matching of RBC transfusions and thus might
have contributed to graft rejection in this series. A
retrospective analysis of archived pretransplantation
sera from unrelated donor HCT recipients showed
that the presence of donor-directed, HLA-specific al-
loantibodies was significantly associated with graft fail-
ure [35]. A similar recent analysis of sera from 386
myeloablative UCBT recipients showed that the
presence of donor-specific antibodies correlated with
Biol Blood Marrow Transplant 18:1265-1272, 2012 1271Unrelated Donor CBT for Children with SCDsignificantly lower neutrophil recovery compared with
those who lacked alloantibodies [36]. The presence of
DSA has also been shown to predict outcomes in dou-
ble umbilical CBTwith higher graft failure and 100 day
mortality in those with preformed DSA [37]. We were
unable to demonstrate the presence of HLA-specific
DSA in any of the 6 patients in whom stored pretrans-
plantation serum samples were available for testing.
van Rood et al. [38] analyzed the impact of admin-
istering a cord blood unit that had a noninherited ma-
ternal HLA antigen (NIMA), which was shared with
a mismatched HLA antigen in the cord blood donor
among patients with hematologic malignancies treated
by UCBT. They showed that having a donor with
a NIMA-shared HLA antigen resulted in lower
transplant-related mortality, and speculated that this
was related to improved neutrophil recovery especially
in those who received a low TNC cell dose. Thus, in
the future, it might be important to perform screening
for HLA-directed alloantibodies and use novel donor
selection criteria to improve the results of CBT for
SCD.
We speculate that a number of modifications
should be explored to improve the rate of engraftment
after UCBT for severe SCD. The use of a myeloabla-
tive regimen might improve outcomes by overcoming
host barriers to engraftment, but this effect can also
cause more short- and long-term toxicity including
marrow aplasia in the setting of a graft rejection. Alter-
natively, we have observed very little toxicity with the
regimen currently employed in the SCURT trial, and
thus have considered modifications that might not
significantly alter the toxicity profile while increasing
the immunosuppressive intensity of the regimen. The
addition of hydroxyurea well before HCT to eradicate
thalassemic clones and/or the addition of thiotepa to
the preparative regimen resulted in lower rejection
rates afterHLA-identical sibling bonemarrow transpl-
antation in advanced thalassemia [39,40] and is
currently being studied in a reduced intensity study
of unrelated CBT for thalassemia. A higher TNC
dose might also improve engraftment [21]. This might
also be accomplished by the use of dual CBU trans-
plantation; however, this approach has not been vali-
dated in the context of a prospective clinical trial
[22,41,42]. Whenever possible, the selection of CB
units that are negative for antigens against which
there are preexisting recipient antibodies should be
pursued. At the present time, the role of NIMA
matching in impacting engraftment in UCBT is
unclear and requires additional investigation. In
summary, because the less stringent need for HLA
matching in CBT might still expand HCT access to
many SCD patients who might not otherwise be able
to pursue HCT, strategies to overcome engraftment
barriers in CBT should be pursued and tested in
clinical trials.ACKNOWLEDGMENTS
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